ACST Stock – (NASDAQ: ACST) is providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the use of its “at the market” equity providing program.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out a “at the market” equity offering program under which Acasti might issue as well as market from time to time the common shares of its having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being offered at prevailing market prices averaging US$1.0747 a share. No securities were sold throughout the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will supply the Company with supplemental flexibility in its continuous review process to explore as well as evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescription drugs using OM3 greasy acids delivered both as free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of efficacy as well as safety for lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for clients with severe HTG.
Forward Looking Statements – ACST Stock
Statements in this press release which aren’t statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions involve known and unknown risks, uncertainties, and other unknown elements that may result in the particular results of Acasti to be materially different from historical success and even as a result of any future outcomes expressed or perhaps implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, people are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the day of this press release. Forward-looking statements in that press release include, but are not confined to, info or statements concerning Acasti’s strategy, future operations as well as the review of its of strategic options.
The forward looking statements contained in this press release are expressly qualified in their entirety by this alerting statement, the “Special Note Regarding Forward Looking Statements” section in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor area of Acasti’s website at www.acastipharma.com. Many forward looking assertions in this press release are available as of the particular date of this particular press release.
ACST Stock – Acasti does not undertake to redesign any such forward looking statements whether as a result of new information, future events or perhaps otherwise, except as called for by law. The forward looking claims contained herein are also subject typically to risks and assumptions and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage